drugset / Trial / NCT01056575
Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4
NaSingle-groupOpen-labelDiagnostic
Summary
This will be an open label, sequential study of midazolam (dose 5 mg orally) followed by midazolam (5 mg orally) given after dosing with OC000459 100 mg twice daily for 6.5 days. Twenty subjects will be included to ensure at least 16 subjects with analysable PK data. PK sampling for midazolam and 4-hydroxymidazolam plasma concentrations will continue for up to and including 24 hours after dosing with midazolam on both occasions.
Timeline
- Start
- 2010-02
- Primary completion
- 2010-04
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TIMAPIPRANT | Small molecule | 100 mg | Oral |
Indications
No indication recorded.